Advanced Cell Technology Share Price - ACTC, RNS News, Articles, Share Price Quotes, Charts, & Stock Market information(OTC:ACTC, )

Advanced Cell Technology
www.advancedcell.com

Description

Advanced Cell Technology is a biotechnology company focused on applying stem cell technology in the field of regenerative medicine to bring effective, patient-specific therapies to the bedside.

News

05/10/11
Advanced Cell Technology to present at World Stem Cell Summit in California
23/09/11
Advanced Cell Technology gets green light for Europe's first human embryonic stem cell trial
28/06/11
Advanced Cell and Roslin to collaborate on developing a stem cell bank
18/06/11
Advanced Cell enrolls first patients in 2 clinical trials for eye disease stem cell treatments
18/05/11
Advanced Cell Technology announces site for Stargardt's stem cell trial
05/05/11
Advanced Cell welcomes decision to lift ban on federal embryonic stem cell research funding
03/05/11
Advanced Cell Technology receives approval for clinical trial location
28/04/11
Advanced Cell files European clinical trial application for Stargardt's treatment
01/04/11
Advanced Cell Technology to be issued key Chinese IP patent for stem cell program
31/03/11
Advanced Cell Technology achieves strongest financial position yet

All News ►

Recent Sector News

Medical Australia completes milestone first animal stem cell treatments in U.K.

The TUTAVet animal stem cell therapy has substantial commercial upside for Medical Australia. Following the completion of the first two procedures in the U.K. the company has generated strong interest from veterinary surgeons keen to trial the technology.
Medical Australia secures first mover advantage in Europe with animal stem cell therapy

Mark Donnison, managing director of Medical Australia, told Proactive Investors today the roll out of a new unique regenerative animal stem cell therapy offering in Europe presents the company with three potential revenue streams.
Medical Australia boosts FY2012 revenue by A$1.5m with new supply agreements

New supply contracts indicate the strong organic revenue growth Medical Australia is experiencing across the business and with further prospects the company is on a solid growth footing for FY2012 and beyond.
Circadian Technologies moves into clinical development phase on approval of IND for cancer drug

The FDA’s approval of Circadian’s Investigational New Drug application for its antibody to treat cancer means the company is now well placed to begin the transition to a clinical development company.
Circadian Technologies: Van Leeuwenhoeck places share price target of $1.97

Van Leeuwenhoeck considers Circadian as "gravely undervalued at current share price of $0.50", and based on a sum-of-the-parts valuation, values the company at A$1.97 - around four times the last traded price - highlighting significant upside potential.
Circadian Technologies looks to royalties on cancer diagnostic test with Healthscope

Healthscope has paid Circadian an upfront fee, and will pay a royalty on sales of the CUP test. The CUP test will be commercially available early next year, ringing in the transition for Circadian into a clinical development company.